UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pathologic response differs between and within tumor sites at the time of interval debulking surgery following neoadjuvant chemotherapy in advanced ovarian cancer

Gynecologic oncology, 2017-06, Vol.145, p.104-104

2017

Volltextzugriff (PDF)

Need for additional training in genetic counseling among gynecologic oncology providers

Gynecologic oncology, 2016-06, Vol.141, p.77-77

2016

Volltextzugriff (PDF)

Prospective patient-elicited value assessments of options in the primary treatment of ovarian cancer

Gynecologic oncology, 2017-06, Vol.145, p.45-46

2017

Volltextzugriff (PDF)

Follow-up study to assess durability of a nursing protocol to improve postpartum inpatient HPV vaccination

Gynecologic oncology, 2017-06, Vol.145, p.163-164

2017

Volltextzugriff (PDF)

Gynecologic oncology patients are ready for telemedicine in routine care: Results from a pre-COVID survey

Gynecologic oncology reports, 2021-11, Vol.38, p.100871-100871, Article 100871

2021

Volltextzugriff (PDF)

Antibiotics and the commensal microbiota: Impact on survival in women with epithelial ovarian cancer

Gynecologic oncology, 2016-06, Vol.141, p.61-61

2016

Volltextzugriff (PDF)

Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated comprehensive cancer center

Gynecologic oncology, 2017-06, Vol.145, p.152-153

2017

Volltextzugriff (PDF)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer

Gynecologic oncology, 2016-06, Vol.141, p.148-149

2016

Volltextzugriff (PDF)

Resource utilization in the final 30 days of life for Medicare patients with ovarian cancer: An opportunity for improvement

Gynecologic oncology, 2019-06, Vol.154, p.219-220

2019

Volltextzugriff (PDF)

Inpatient chemotherapy for gynecologic cancer: When is it worth it?

Gynecologic oncology, 2020-10, Vol.159, p.317-318

2020

Volltextzugriff (PDF)

Improving the surgical experience in gynecologic oncology patients with use of patient engagement technology: A prospective cohort study

Gynecologic oncology, 2020-10, Vol.159, p.296-296

2020

Volltextzugriff (PDF)

Pelvic exenteration for cervical cancer: An endangered skill?

Gynecologic oncology, 2018-06, Vol.149, p.80-80

2018

Volltextzugriff (PDF)

Financial toxicity begins early in the treatment course and correlates with gynecologic cancer patients’ quality of life and self-reported health status

Gynecologic oncology, 2020-10, Vol.159, p.244-245

2020

Volltextzugriff (PDF)

Characterizing patient-reported outcomes as standard of care

Gynecologic oncology, 2020-10, Vol.159, p.271-271

2020

Volltextzugriff (PDF)

Interventions targeting work-related concerns and linkage to appropriate financial resources are needed for gynecologic cancer patients starting a new line of treatment

Gynecologic oncology, 2020-10, Vol.159, p.250-250

2020

Volltextzugriff (PDF)

Shorter interval to subsequent therapy following a PARP inhibitor is associated with poor tolerance of the subsequent therapy (post-PARPi therapy)

Gynecologic oncology, 2020-10, Vol.159, p.114-115

2020

Volltextzugriff (PDF)

Moderate/severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management

Gynecologic oncology, 2020-10, Vol.159, p.311-311

2020

Volltextzugriff (PDF)

Moderate/Severe Distress in Half of Ovarian Cancer Patients Undergoing Treatment Highlights a Need for More Proactive Symptom and Psychosocial Management

Gynecologic oncology, 2020-07, Vol.158 (1), p.e11-e11

2020

Volltextzugriff (PDF)

More severe financial toxicity correlated with worse quality of life in gynecologic cancer patients on treatment

Gynecologic oncology, 2019-06, Vol.154, p.165-165

2019

Volltextzugriff (PDF)

The cost of treatment: Financial toxicity and opportunity costs among gynecologic cancer patients starting a new line of treatment

Gynecologic oncology, 2019-06, Vol.154, p.6-6

2019

Volltextzugriff (PDF)

The value of financial and time costs to ovarian cancer patients when making decisions about their care

Gynecologic oncology, 2019-06, Vol.154, p.167-167

2019

Volltextzugriff (PDF)

Low knowledge of coverage benefits and insurance characteristics do not increase the risk of financial toxicity in the gynecologic cancer population

Gynecologic oncology, 2019-06, Vol.154, p.167-167

2019

Volltextzugriff (PDF)

Bevacizumab, TKI, or PARPi? A targeted approach using composite value-based endpoints and biomarkers to individualize care for platinum-sensitive recurrent ovarian cancer (PSROC)

Gynecologic oncology, 2018-06, Vol.149, p.10-11

2018

Volltextzugriff (PDF)

Do patients care who is paying for their ovarian cancer treatment? Patient perspectives on value-based assessments

Gynecologic oncology, 2018-06, Vol.149, p.124-124

2018

Volltextzugriff (PDF)

Setting the bar: Compliance with ovarian cancer quality indicators at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center (CCC)

Gynecologic oncology, 2015-04, Vol.137, p.41-42

2015

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(53)
Tagungsberichte
(3)

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pathologic response differs between and within tumor sites at the time of interval debulking surgery following neoadjuvant chemotherapy in advanced ovarian cancer

Need for additional training in genetic counseling among gynecologic oncology providers

Prospective patient-elicited value assessments of options in the primary treatment of ovarian cancer

Follow-up study to assess durability of a nursing protocol to improve postpartum inpatient HPV vaccination

Gynecologic oncology patients are ready for telemedicine in routine care: Results from a pre-COVID survey

Antibiotics and the commensal microbiota: Impact on survival in women with epithelial ovarian cancer

Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated comprehensive cancer center

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer

Resource utilization in the final 30 days of life for Medicare patients with ovarian cancer: An opportunity for improvement

Inpatient chemotherapy for gynecologic cancer: When is it worth it?

Improving the surgical experience in gynecologic oncology patients with use of patient engagement technology: A prospective cohort study

Pelvic exenteration for cervical cancer: An endangered skill?

Financial toxicity begins early in the treatment course and correlates with gynecologic cancer patients’ quality of life and self-reported health status

Characterizing patient-reported outcomes as standard of care

Interventions targeting work-related concerns and linkage to appropriate financial resources are needed for gynecologic cancer patients starting a new line of treatment

Shorter interval to subsequent therapy following a PARP inhibitor is associated with poor tolerance of the subsequent therapy (post-PARPi therapy)

Moderate/severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management

Moderate/Severe Distress in Half of Ovarian Cancer Patients Undergoing Treatment Highlights a Need for More Proactive Symptom and Psychosocial Management

More severe financial toxicity correlated with worse quality of life in gynecologic cancer patients on treatment

The cost of treatment: Financial toxicity and opportunity costs among gynecologic cancer patients starting a new line of treatment

The value of financial and time costs to ovarian cancer patients when making decisions about their care

Low knowledge of coverage benefits and insurance characteristics do not increase the risk of financial toxicity in the gynecologic cancer population

Bevacizumab, TKI, or PARPi? A targeted approach using composite value-based endpoints and biomarkers to individualize care for platinum-sensitive recurrent ovarian cancer (PSROC)

Do patients care who is paying for their ovarian cancer treatment? Patient perspectives on value-based assessments

Setting the bar: Compliance with ovarian cancer quality indicators at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center (CCC)

Suchergebnisse filtern